Gemin X

Gemin X Pharmaceuticals developed cancer therapeutics focussed on the cell death pathway. The lead candidate, GX15-070, reinitiates programmed cell death and apoptosis. Gemin X was acquired by Cephalon in 2011 for $525 million.




Acquired by Cephalon in 2011 for $525 million

Related companies

Leave a Comment

Your email address will not be published. Required fields are marked *